Testing for qualitative interactions between treatment effects and patient subsets.
about
Gene-environment interactions in cancer epidemiology: a National Cancer Institute Think Tank reportPIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisEffect of epidural anesthesia and analgesia on perioperative outcome: a randomized, controlled Veterans Affairs cooperative studySubgroup Identification in Personalized Treatment of Alcohol Dependence.Age-related crossover in breast cancer incidence rates between black and white ethnic groups.Controversies about sponsor initiated re-analyses of clinical trial data in the licensing process.A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.A note on partial covariate-adjustment and design considerations in noninferiority trials when patient-level data are not available.Use of auxiliary covariates in estimating a biomarker-adjusted treatment effect model with clinical trial data.Analyzing longitudinal data to characterize the accuracy of markers used to select treatmentExtrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods.Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trialsDetecting treatment-by-centre interaction in multi-centre clinical trials.'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Effectiveness of chest physiotherapy in infants hospitalized with acute bronchiolitis: a multicenter, randomized, controlled trial.Principles for designing randomized preventive trials in mental health: an emerging developmental epidemiology paradigm.Mortality in the randomized, controlled lung intergroup trial of isotretinoinSTAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects.Subgroup identification from randomized clinical trial data.Multicentre trials: a US regulatory perspective.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialDetecting moderator effects using subgroup analyses.A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension.Placebo controlled, prospectively randomized, double-blinded study for the investigation of the effectiveness and safety of the acoustic wave therapy (AWT(®)) for cellulite treatment.Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with PalonosetronAdjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.Pattern mixture models for clinical validation of biomarkers in the presence of missing data.Treatment Heterogeneity and Individual Qualitative InteractionThe Use of Covariates and Random Effects in Evaluating Predictive Biomarkers Under a Potential Outcome Framework.Using decision lists to construct interpretable and parsimonious treatment regimes.On Bayesian methods of exploring qualitative interactions for targeted treatment.Statistical considerations for noninferiority/equivalence trials in vaccine development.A robust method for estimating optimal treatment regimes.Estimating Optimal Treatment Regimes from a Classification Perspective.Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive BiomarkerSequential advantage selection for optimal treatment regimeOmega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.Monitoring futility in a two-by-two factorial design: the SPS3 experience.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
P2860
Q24289531-83292B5A-AA59-409D-8ECA-E76D77847A72Q26992267-0E98F1B8-F339-41B4-908D-7F3AFA2A1365Q28360401-33D78D57-B760-441C-AB58-D442D2F3FE58Q30279256-5458ABF0-7FD4-46B1-926E-5393C5383FDCQ30485944-CFA5989D-6AD2-44D3-9D2C-E10B0D78CFCBQ30581193-1F5D145E-BDB3-4E63-8191-A6A980513158Q30612579-7B3D9B26-05A1-47E1-B426-C20749560305Q30662286-115D5E48-98AB-4970-B7D4-C3F825C3A1FFQ30717235-81F75757-9EA0-4F61-9157-1FA7A0B28FC8Q30776465-C262B63D-5D50-42C4-90F4-AACE1B4AF8E0Q31060832-9388EBCE-9DE6-44A2-A203-84BC5AED400CQ31142712-4A402650-A587-4E39-A2BC-3D9B8058549EQ31910371-2E973F92-448B-46FA-98BB-CFFE42D9F88DQ33261643-EC2A217C-E82A-4B11-92BA-3CC25A336502Q33572303-6D1DFDBA-A45C-4B92-BFE4-D49A0B762C88Q33712001-BCCC0B2F-4146-40EB-B08A-8E182F362297Q33838552-99EDB12D-2B3E-435E-99AB-C0012EB037F6Q33895618-8BD4F521-176B-4F83-8A96-2A76EF034DB2Q33904977-483CEA66-ECEB-4814-80DE-45C490A621C1Q33981752-9AC78885-757E-47CC-855A-BB379F57FCF5Q33987966-C6495671-4646-4868-B3B6-27E9D7F82492Q34139672-D86E85B8-BE5C-4286-8E33-64275EFAA741Q34184426-0AD8D8DF-F2CE-4B29-A473-5481D841112BQ34525968-27283C2F-28F4-4E67-A24D-FE75C1A5E9B8Q34728984-39D3BC84-C346-48D5-A0D5-1E1EE845C6F7Q35904224-A02D580D-6140-42FB-963C-CA4ECD808A43Q35925244-7F6F3791-2DF8-49CD-ADBE-CA9C1852CFF5Q36361076-CF486B5B-500B-476E-BD6E-D319AD93C808Q36426619-FB247E56-1C2A-4D52-9952-118D583F2202Q36467574-D043008E-D38B-465F-939A-83108E104A4BQ36470116-FEAE0A85-A050-47AC-ABD5-C680A4C06C46Q36482037-643E0D2C-4679-4D54-A4AF-34F4DDCE4E91Q36558368-7404BCD7-2ED3-465C-BDA3-4101DB12921DQ36567700-440A10E9-EB0C-4F28-80E6-4456F842F9F1Q36806557-372EBF84-1A50-4A59-9773-8E5FC9471B2DQ36868328-1CE3E781-CB67-4194-9470-A520A557A8C9Q37016184-2B1B3D80-2D6C-4F6B-AF38-AA041400A1CAQ37053948-35C89253-1BF4-4BC1-90E6-940EE7853F2AQ37064316-F106C140-C1E2-4B63-B113-06D2AF6FFF8BQ37075929-C1EFBD2E-9924-46FC-875C-E0CC25FC0461
P2860
Testing for qualitative interactions between treatment effects and patient subsets.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
Testing for qualitative interactions between treatment effects and patient subsets.
@en
Testing for qualitative interactions between treatment effects and patient subsets.
@nl
type
label
Testing for qualitative interactions between treatment effects and patient subsets.
@en
Testing for qualitative interactions between treatment effects and patient subsets.
@nl
prefLabel
Testing for qualitative interactions between treatment effects and patient subsets.
@en
Testing for qualitative interactions between treatment effects and patient subsets.
@nl
P356
P1433
P1476
Testing for qualitative interactions between treatment effects and patient subsets.
@en
P304
P356
10.2307/2530862
P407
P577
1985-06-01T00:00:00Z